ERBB2 and neoplasm: Exploratory analyses of clinicopathological features and HER2-evolution showed that patients with histological grade III were more likely to develop HER2-loss, and those with Ki-67 > 14% were more likely to develop HER2-gain This may be related to the higher tumour heterogeneity in these patients.